Clinical Trials Directory

Trials / Completed

CompletedNCT02428478

Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A

The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Brigham and Women's Hospital · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on genioglossus muscle activity (EMG GG) during sleep in healthy control participants.

Detailed description

Two overnight sleep studies, a placebo night and a drug night, will be performed approximately one week apart in random order. The placebo or drug will be administered 2 hours before lights out. At least 15 minutes of quiet wakefulness will be recorded to quantify the participant's awake EMG GG activity. Participants will then sleep in the lateral position to minimize pharyngeal resistance similar to previous studies of this kind. The same will be done for stable non-rapid eye movement (NREM) and rapid eye movement (REM) sleep (free of arousals and other artifacts). Both NREM and REM sleep will be analyzed, recognizing that REM is less frequent on these drugs. During the second part of the night, the participants will be connected to a modified continuous positive airway pressure (CPAP) machine (Pcrit3000, Respironics) which can provide a wide range of pressures between 20 and -20 cm H2O in order to modify upper airway pressure and measure change in EMG GG as a function of epiglottic pressure (muscle responsiveness).

Conditions

Interventions

TypeNameDescription
DRUGDesipramine200 mg administered 2 hours before normal sleep time
DRUGPlaceboPlacebo-matching desipramine administered 2 hours before normal sleep time

Timeline

Start date
2015-03-01
Primary completion
2015-11-01
Completion
2016-03-01
First posted
2015-04-28
Last updated
2017-03-30
Results posted
2017-03-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02428478. Inclusion in this directory is not an endorsement.